To modeling the pharmacokinetic-pharmacodynamic(PK-PD) simulation with the plasma concentration and the transporter occupancy from OCD patients treated with escitalopram. To examine the effect of G2677T/A single nucleotide polymorphism(SNP) of ABCB1 gene to the PK-PD modeling in OCD patients treated with escitalopram.
Description: scale for the severity of Obsessive-compulsive symptoms
Measure: Yale-Brown Obsessive Compulsive Scale(Y-BOCS) Score Time: baselineDescription: serotonin transporter occupancy measured at 5 hour and 24 hour after oral dose of escitalopram
Measure: serotonin transporter occupancy Time: within the first 24hrs after oral administration of escitalopramDescription: plasma concentration of escitalopram at baseline, 1, 2, 3, 5, 8, 10, 24, 48, 72 hour after oral dose of escitalopram
Measure: escitalopram plasma concentration Time: within 72 hours after oral administration of escitalopramOther
There is one SNP
To examine the effect of G2677T/A single nucleotide polymorphism(SNP) of ABCB1 gene to the PK-PD modeling in OCD patients treated with escitalopram. --- G2677T ---
To genotype G2677T/A SNP of ABCB1 gene in OCD patients treated with escitalopram. --- G2677T ---